Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812
27 août 2020 07h59 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
25 août 2020 07h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases,...
Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer's Clinical Trials Consortium
08 juin 2020 08h15 HE
|
Cognition Therapeutics, Inc.
New York, June 08, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
Neuroprosthetics Market To Reach USD 15.8 Billion By 2026 | Reports And Data
14 janv. 2020 10h01 HE
|
Reports and Data
New York, Jan. 14, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Neuroprosthetics market was valued at USD 6.1 Billion in 2018 and is expected to reach...
Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019
20 nov. 2019 08h03 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Streetwise Reports Publishes 'Could There Finally Be an Effective Treatment for Alzheimer's Disease?'
07 nov. 2019 07h00 HE
|
Streetwise Reports Llc
SAN FRANCISCO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Finding an effective treatment for Alzheimer's disease has been elusive as many seemingly promising avenues of research did not prove out in clinical...
Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference
10 sept. 2019 08h16 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China
24 juil. 2019 09h27 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, July 24, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts
09 juil. 2019 08h02 HE
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 09, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens
05 avr. 2019 08h02 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, April 05, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...